Overview

A Randomized, Single-Center, Single-Blind, Placebo Controlled, Investigator Initiated Trial to Evaluate the Efficacy of PanCytoVir™ 500 mg Twice Daily and 1000 mg Twice Daily for the Treatment of Non-Hospitalized Patients With COVID-19 Infection

Status:
Not yet recruiting

Trial end date:
2022-10-30

Target enrollment:

Participant gender:

Summary

This is a randomized, single-center, single-blind, placebo controlled, study to evaluate efficacy of PanCytoVir™ 500 mg twice daily and 1000 mg twice daily for the treatment of non-hospitalized patients with COVID-19 infection.

Phase:

Phase 2

Details

Lead Sponsor:

TrippBio, Inc.

Treatments:

Probenecid